MYSTIC trial results to be later than expected

AstraZeneca Plc said that final data from its Phase 3 MYSTIC trial which is testing a combination immunotherapy for non-small cell lung cancer, are now expected in the second half of the year, rather than in the first half.

Full text available to subscribers only. Click here for information on subscribing to MedNous.


United Kingdom